$EDGE Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in PDS Biotechnology Corp.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in PDS Biotechnology Corp. Get notifications about new insider transactions in PDS Biotechnology Corp for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 17 2021 | EDGE | PDS Biotechnology ... | Ali-Jackson Kamil | Option Exercise | A | 9.95 | 9,000 | 89,550 | 9,000 | ||
Jun 17 2021 | EDGE | PDS Biotechnology ... | Ali-Jackson Kamil | Buy | P | 8.50 | 11,764 | 99,994 | 11,764 | 0 to 11.8 K | |
Dec 09 2020 | EDGE | PDS Biotechnology ... | CONN GREGORY | Chief Scientific Of ... | Option Exercise | A | 2.43 | 122,400 | 297,432 | 122,400 | |
Dec 09 2020 | EDGE | PDS Biotechnology ... | WOOD LAUREN | Chief Medical Offic ... | Option Exercise | A | 2.43 | 210,500 | 511,515 | 210,500 | |
Dec 09 2020 | EDGE | PDS Biotechnology ... | King Michael N. | Interim CFO | Option Exercise | A | 2.43 | 50,000 | 121,500 | 50,000 | |
Dec 09 2020 | EDGE | PDS Biotechnology ... | BEDU-ADDO FRANK | President/CEO | Option Exercise | A | 2.43 | 707,800 | 1,719,954 | 707,800 | |
Nov 06 2020 | EDGE | PDS Biotechnology ... | BRAWLEY OTIS W | Option Exercise | A | 2.09 | 9,000 | 18,810 | 9,000 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | Glover Steve C | Option Exercise | A | 1.45 | 9,000 | 13,050 | 9,000 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | Freitag Gregory Gene | Option Exercise | A | 1.45 | 9,000 | 13,050 | 9,000 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | SYKES RICHARD | Option Exercise | A | 1.45 | 9,000 | 13,050 | 9,000 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | Ali-Jackson Kamil | Option Exercise | A | 1.45 | 3,033 | 4,398 | 3,033 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | WOOD LAUREN | Chief Medical Offic ... | Option Exercise | A | 1.45 | 35,000 | 50,750 | 35,000 | |
Jun 25 2020 | EDGE | PDS Biotechnology ... | Bloomquist DeLyle W | Option Exercise | A | 1.45 | 9,000 | 13,050 | 9,000 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | Iliev Ilian | Option Exercise | A | 1.45 | 1,874 | 2,717 | 1,874 | ||
Jun 25 2020 | EDGE | PDS Biotechnology ... | CONN GREGORY | Chief Scientific Of ... | Option Exercise | A | 1.45 | 35,000 | 50,750 | 35,000 | |
Jun 25 2020 | EDGE | PDS Biotechnology ... | BEDU-ADDO FRANK | President/CEO | Option Exercise | A | 1.45 | 125,000 | 181,250 | 125,000 | |
Apr 09 2020 | EDGE | PDS Biotechnology ... | Iliev Ilian | Option Exercise | A | 0.72 | 4,500 | 3,240 | 4,500 | ||
Apr 09 2020 | EDGE | PDS Biotechnology ... | Iliev Ilian | Option Exercise | A | 0.72 | 4,500 | 3,240 | 4,500 | ||
Feb 24 2020 | EDGE | PDS Biotechnology ... | Ali-Jackson Kamil | Option Exercise | A | 1.31 | 9,000 | 11,790 | 9,000 | ||
Jul 01 2019 | EDGE | PDS Biotechnology ... | Glover Steve C | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | Glover Steve C | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | SYKES RICHARD | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | SYKES RICHARD | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | LOUGHLIN JAMES J | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | LOUGHLIN JAMES J | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | Freitag Gregory Gene | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | BEDU-ADDO FRANK | President/CEO | Option Exercise | A | 5.99 | 100,000 | 599,000 | 100,000 | |
Jul 01 2019 | EDGE | PDS Biotechnology ... | Bloomquist DeLyle W | Director | Option Exercise | A | 5.99 | 9,000 | 53,910 | 9,000 | |
Jun 07 2019 | EDGE | PDS Biotechnology ... | WOOD LAUREN | Chief Medical Offic ... | Option Exercise | A | 6.39 | 62,715 | 400,749 | 62,715 | |
Jun 07 2019 | EDGE | PDS Biotechnology ... | CONN GREGORY | Chief Scientific Of ... | Option Exercise | A | 6.39 | 40,000 | 255,600 | 40,000 | |
Jun 07 2019 | EDGE | PDS Biotechnology ... | Saik Andrew | Chief Financial Off ... | Option Exercise | A | 6.39 | 62,715 | 400,749 | 62,715 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Director | Buy | M | 0.00 | 10,000 | 0 | 580,602 | 570.6 K to 580.6 K (+1.75 %) |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Buy | M | 0.00 | 10,000 | 0 | 48,661 | 38.7 K to 48.7 K (+25.87 %) |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Option Exercise | M | 0.00 | 82,999 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Buy | M | 0.00 | 82,999 | 0 | 82,999 | 0 to 83 K |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Ratcliffe Liam | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Ratcliffe Liam | Director | Buy | M | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Option Exercise | M | 0.00 | 49,766 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Buy | M | 0.00 | 49,766 | 0 | 59,766 | 10 K to 59.8 K (+497.66 %) |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | M | 0.00 | 10,000 | 0 | 26,625 | 16.6 K to 26.6 K (+60.15 %) |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Option Exercise | M | 0.00 | 169,032 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Buy | M | 0.00 | 169,032 | 0 | 239,268 | 70.2 K to 239.3 K (+240.66 %) |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Buy | M | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Buy | M | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Crane Rosemary A | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | Crane Rosemary A | Director | Buy | M | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | M | 0.00 | 20,000 | 0 | 0 | |
Mar 18 2019 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | M | 0.00 | 20,000 | 0 | 678,075 | 658.1 K to 678.1 K (+3.04 %) |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Crane Rosemary A | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Ratcliffe Liam | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 0.00 | 41,666 | 0 | 41,666 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 0.00 | 41,666 | 0 | 41,666 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Option Exercise | A | 0.00 | 82,999 | 0 | 82,999 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Option Exercise | A | 0.00 | 82,999 | 0 | 82,999 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Wyant Alyssa | SVP Regulatory Affa ... | Option Exercise | A | 0.00 | 49,766 | 0 | 49,766 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | A | 0.00 | 20,000 | 0 | 20,000 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Option Exercise | A | 0.00 | 59,833 | 0 | 59,833 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Option Exercise | A | 0.00 | 169,032 | 0 | 169,032 | |
Aug 15 2018 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Option Exercise | A | 0.00 | 49,766 | 0 | 49,766 | |
Jun 21 2018 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Ratcliffe Liam | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 1.10 | 83,334 | 91,667 | 83,334 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | A | 1.10 | 40,000 | 44,000 | 40,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 1.10 | 83,334 | 91,667 | 83,334 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | A | 1.10 | 40,000 | 44,000 | 40,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Crane Rosemary A | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 1.10 | 20,000 | 22,000 | 20,000 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Option Exercise | A | 1.10 | 338,068 | 371,875 | 338,068 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Option Exercise | A | 1.10 | 166,001 | 182,601 | 166,001 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Option Exercise | A | 1.10 | 119,667 | 131,634 | 119,667 | |
Jun 20 2018 | EDGE | Edge Therapeutics, ... | Wyant Alyssa | SVP Regulatory Affa ... | Option Exercise | A | 1.10 | 99,534 | 109,487 | 99,534 | |
Mar 30 2018 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Sell | J | 0.00 | 58,476 | 0 | 0 | 58.5 K to 0 (-100.00 %) |
Mar 22 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Sell | S | 16.41 | 2,500 | 41,025 | 570,602 | 573.1 K to 570.6 K (-0.44 %) |
Mar 21 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Sell | S | 16.52 | 2,500 | 41,300 | 573,102 | 575.6 K to 573.1 K (-0.43 %) |
Mar 21 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Sell | S | 16.47 | 5,000 | 82,350 | 575,602 | 580.6 K to 575.6 K (-0.86 %) |
Mar 21 2018 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Sell | S | 16.66 | 2,500 | 41,650 | 580,602 | 583.1 K to 580.6 K (-0.43 %) |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Option Exercise | A | 14.98 | 65,000 | 973,700 | 65,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Option Exercise | A | 14.98 | 90,000 | 1,348,200 | 90,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | BRENNAN DANIEL | Chief Operating Off ... | Option Exercise | A | 14.98 | 90,000 | 1,348,200 | 90,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Option Exercise | A | 14.98 | 50,000 | 749,000 | 50,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | Wyant Alyssa | SVP Regulatory Affa ... | Option Exercise | A | 14.98 | 50,000 | 749,000 | 50,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 14.98 | 25,000 | 374,500 | 25,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Option Exercise | A | 14.98 | 280,000 | 4,194,400 | 280,000 | |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 15.08 | 2,500 | 37,700 | 70,236 | 72.7 K to 70.2 K (-3.44 %) |
Mar 05 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 14.81 | 2,500 | 37,025 | 72,736 | 75.2 K to 72.7 K (-3.32 %) |
Feb 23 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 15.37 | 2,500 | 38,425 | 75,236 | 77.7 K to 75.2 K (-3.22 %) |
Feb 23 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 15.47 | 2,500 | 38,675 | 77,736 | 80.2 K to 77.7 K (-3.12 %) |
Feb 02 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 12.96 | 2,500 | 32,400 | 80,236 | 82.7 K to 80.2 K (-3.02 %) |
Feb 02 2018 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 13.14 | 2,500 | 32,850 | 82,736 | 85.2 K to 82.7 K (-2.93 %) |
Dec 05 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.68 | 2,500 | 24,200 | 90,236 | 92.7 K to 90.2 K (-2.70 %) |
Dec 05 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.97 | 2,500 | 24,925 | 92,736 | 95.2 K to 92.7 K (-2.63 %) |
Dec 05 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.92 | 2,500 | 24,800 | 95,236 | 97.7 K to 95.2 K (-2.56 %) |
Nov 22 2017 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Sell | S | 10.00 | 3,361 | 33,610 | 0 | 3.4 K to 0 (-100.00 %) |
Nov 03 2017 | EDGE | Edge Therapeutics, ... | Saik Andrew | Chief Financial Off ... | Option Exercise | A | 10.73 | 200,000 | 2,146,000 | 200,000 | |
Nov 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.86 | 2,500 | 27,150 | 97,736 | 100.2 K to 97.7 K (-2.49 %) |
Nov 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.94 | 2,500 | 27,350 | 100,236 | 102.7 K to 100.2 K (-2.43 %) |
Nov 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.92 | 2,500 | 27,300 | 102,736 | 105.2 K to 102.7 K (-2.38 %) |
Oct 04 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 11.14 | 2,500 | 27,850 | 105,236 | 107.7 K to 105.2 K (-2.32 %) |
Oct 04 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.93 | 2,500 | 27,325 | 107,736 | 110.2 K to 107.7 K (-2.27 %) |
Oct 04 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.81 | 2,500 | 27,025 | 110,236 | 112.7 K to 110.2 K (-2.22 %) |
Sep 20 2017 | EDGE | Edge Therapeutics, ... | Crane Rosemary A | Director | Option Exercise | A | 9.43 | 30,000 | 282,900 | 30,000 | |
Sep 06 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.31 | 2,500 | 25,775 | 112,736 | 115.2 K to 112.7 K (-2.17 %) |
Sep 06 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.94 | 2,500 | 24,850 | 115,236 | 117.7 K to 115.2 K (-2.12 %) |
Sep 06 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.37 | 2,500 | 25,925 | 117,736 | 120.2 K to 117.7 K (-2.08 %) |
Aug 29 2017 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Sell | S | 10.42 | 2,500 | 26,050 | 3,361 | 5.9 K to 3.4 K (-42.65 %) |
Aug 24 2017 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Sell | S | 10.39 | 1,000 | 10,390 | 5,861 | 6.9 K to 5.9 K (-14.58 %) |
Aug 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.40 | 2,500 | 26,000 | 120,236 | 122.7 K to 120.2 K (-2.04 %) |
Aug 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.53 | 2,500 | 26,325 | 122,736 | 125.2 K to 122.7 K (-2.00 %) |
Aug 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.65 | 2,500 | 26,625 | 125,236 | 127.7 K to 125.2 K (-1.96 %) |
Jul 10 2017 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | X | 2.39 | 12,530 | 29,947 | 0 | |
Jul 10 2017 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Buy | X | 2.39 | 12,530 | 29,947 | 658,075 | 645.5 K to 658.1 K (+1.94 %) |
Jul 06 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.08 | 2,500 | 25,200 | 127,736 | 130.2 K to 127.7 K (-1.92 %) |
Jul 06 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.21 | 2,500 | 25,525 | 130,236 | 132.7 K to 130.2 K (-1.88 %) |
Jul 06 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 10.27 | 2,500 | 25,675 | 132,736 | 135.2 K to 132.7 K (-1.85 %) |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | BARER SOL J | Director | Option Exercise | A | 10.15 | 30,000 | 304,500 | 30,000 | |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | BLECH ISAAC | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | Conti Kurt G | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | HEALY JAMES | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | Ratcliffe Liam | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
Jun 21 2017 | EDGE | Edge Therapeutics, ... | Spiegel Robert J. | Director | Option Exercise | A | 10.15 | 15,000 | 152,250 | 15,000 | |
May 09 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 11.10 | 100 | 1,110 | 135,236 | 135.3 K to 135.2 K (-0.07 %) |
Mar 15 2017 | EDGE | Edge Therapeutics, ... | MIDDLEKAUFF W BRADFORD | Senior VP, GC and S ... | Option Exercise | A | 8.86 | 52,500 | 465,150 | 52,500 | |
Mar 15 2017 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Option Exercise | A | 8.86 | 110,000 | 974,600 | 110,000 | |
Mar 15 2017 | EDGE | Edge Therapeutics, ... | MARCHIO ALBERT N II | Chief Accounting & ... | Option Exercise | A | 8.86 | 47,500 | 420,850 | 47,500 | |
Mar 15 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Option Exercise | A | 8.86 | 267,500 | 2,370,050 | 267,500 | |
Mar 15 2017 | EDGE | Edge Therapeutics, ... | Faleck Herbert J | Chief Medical Offic ... | Option Exercise | A | 8.86 | 110,000 | 974,600 | 110,000 | |
Mar 15 2017 | EDGE | Edge Therapeutics, ... | Yaman Alpaslan | V.P., Technical Ops ... | Option Exercise | A | 8.86 | 40,000 | 354,400 | 40,000 | |
Mar 13 2017 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | X | 2.39 | 1,567 | 3,745 | 0 | |
Mar 13 2017 | EDGE | Edge Therapeutics, ... | Einhorn Andrew J. | Chief Financial Off ... | Buy | X | 2.39 | 1,567 | 3,745 | 43,223 | 41.7 K to 43.2 K (+3.76 %) |
Mar 07 2017 | EDGE | Edge Therapeutics, ... | LOUGHLIN JAMES J | Director | Buy | P | 9.24 | 3,000 | 27,720 | 6,000 | 3 K to 6 K (+100.00 %) |
Mar 02 2017 | EDGE | Edge Therapeutics, ... | Wyant Alyssa | SVP Regulatory Affa ... | Option Exercise | A | 9.81 | 80,000 | 784,800 | 80,000 | |
Feb 08 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.52 | 1,500 | 14,280 | 245,479 | 247 K to 245.5 K (-0.61 %) |
Feb 07 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.52 | 1,500 | 14,280 | 246,979 | 248.5 K to 247 K (-0.60 %) |
Feb 07 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.69 | 1,500 | 14,535 | 248,479 | 250 K to 248.5 K (-0.60 %) |
Feb 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.61 | 1,500 | 14,415 | 249,979 | 251.5 K to 250 K (-0.60 %) |
Feb 03 2017 | EDGE | Edge Therapeutics, ... | Leuthner Brian A | President and CEO | Sell | S | 9.38 | 1,500 | 14,070 | 251,479 | 253 K to 251.5 K (-0.59 %) |
Jan 25 2017 | EDGE | Edge Therapeutics, ... | Macdonald R. Loch | Chief Scientific Of ... | Option Exercise | M | 2.04 | 25,000 | 51,000 | 75,504 |